Journal Article
. 2012 Apr;106(11).
doi: 10.1038/bjc.2012.166.

Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer

S Barton 1 L Zabaglo  R A'Hern  N Turner  T Ferguson  S O'Neill  M Hills  I Smith  M Dowsett  
Affiliations
  • PMID: 22531639
  •     28 References
  •     25 citations

Abstract

Background: The immunohistochemical (IHC) 4+C score is a cost-effective prognostic tool that uses clinicopathologic factors and four standard IHC assays: oestrogen receptor (ER), PR, HER2 and Ki67. We assessed its utility in personalising breast cancer treatment in a clinical practice setting, through comparison with Adjuvant! Online (AoL) and the Nottingham Prognostic Index (NPI).

Methods: We prospectively gathered clinicopathologic data for postmenopausal patients with hormone receptor-positive, HER2-negative, N0-3 resected early breast cancer treated consecutively at our institution. We retrospectively calculated and compared prognostic scores. The primary endpoint was the proportion of patients reclassified from AoL-defined intermediate-risk by application of the IHC4+C score.

Results: The median age of the 101 patients included in the analysis was 63. In all, 15 of the 26 patients classified as intermediate-risk by AoL were reallocated to a low-risk group by application of the IHC4+C score and no patient was reclassified as high-risk group. Of the 59 patients classified as intermediate-risk group by the NPI, 24 were reallocated to a low-risk group and 13 to a high-risk group.

Conclusion: IHC4+C reclassifies more than half of the patients stratified as being in intermediate-risk group by the AoL and NPI. The use of IHC4+C may substantially improve decision-making on adjuvant chemotherapy.

Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution.
G D'Eredita', C Giardina, +2 authors, F Ferrarese.
Eur J Cancer, 2001 Apr 06; 37(5). PMID: 11290434
Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.
P M Ravdin, L A Siminoff, +4 authors, H L Parker.
J Clin Oncol, 2001 Feb 22; 19(4). PMID: 11181660
Highly Cited.
The Nottingham Prognostic Index in primary breast cancer.
M H Galea, R W Blamey, C E Elston, I O Ellis.
Breast Cancer Res Treat, 1992 Jan 01; 22(3). PMID: 1391987
Highly Cited.
The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG).
I Balslev, C K Axelsson, +3 authors, H T Mouridsen.
Breast Cancer Res Treat, 1994 Jan 01; 32(3). PMID: 7865856
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet, 1998 May 30; 351(9114). PMID: 9605801
Highly Cited.
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet, 1998 Sep 30; 352(9132). PMID: 9752815
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
Ivo A Olivotto, Chris D Bajdik, +6 authors, Karen A Gelmon.
J Clin Oncol, 2005 Apr 20; 23(12). PMID: 15837986
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
Laurel A Habel, Steven Shak, +12 authors, Charles P Quesenberry.
Breast Cancer Res, 2006 Jun 02; 8(3). PMID: 16737553    Free PMC article.
Highly Cited.
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C Wolff, M Elizabeth H Hammond, +22 authors, College of American Pathologists.
J Clin Oncol, 2006 Dec 13; 25(1). PMID: 17159189
Highly Cited.
Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999.
R W Blamey, I O Ellis, +8 authors, C W Elston.
Eur J Cancer, 2007 Feb 27; 43(10). PMID: 17321736
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, +11 authors, Steven Shak.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212256
Highly Cited.
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, +29 authors, Antonio C Wolff.
J Clin Oncol, 2010 Apr 21; 28(16). PMID: 20404251    Free PMC article.
Highly Cited. Systematic Review.
Comparative validation of the SP6 antibody to Ki67 in breast cancer.
Lila Zabaglo, Janine Salter, +5 authors, Mitch Dowsett.
J Clin Pathol, 2010 Jul 31; 63(9). PMID: 20671052
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Jack Cuzick, Ivana Sestak, +5 authors, ATAC/LATTE investigators.
Lancet Oncol, 2010 Nov 23; 11(12). PMID: 21087898
Highly Cited.
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Gong Tang, Steven Shak, +6 authors, Norman Wolmark.
Breast Cancer Res Treat, 2011 Jan 12; 127(1). PMID: 21221771    Free PMC article.
Predictive algorithms for adjuvant therapy: TransATAC.
Mitch Dowsett, Janine Salter, +6 authors, Jack Cuzick.
Steroids, 2011 Apr 08; 76(8). PMID: 21470560
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Jack Cuzick, Mitch Dowsett, +10 authors, John F Forbes.
J Clin Oncol, 2011 Oct 13; 29(32). PMID: 21990413
Highly Cited.
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.
Mitch Dowsett, Torsten O Nielsen, +19 authors, International Ki-67 in Breast Cancer Working Group.
J Natl Cancer Inst, 2011 Oct 01; 103(22). PMID: 21960707    Free PMC article.
Highly Cited.
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Mitch Dowsett, Craig Allred, +17 authors, Aman Buzdar.
J Clin Oncol, 2008 Jan 30; 26(7). PMID: 18227529
Highly Cited.
The Nottingham prognostic index for invasive carcinoma of the breast.
Andrew H S Lee, Ian O Ellis.
Pathol Oncol Res, 2008 Jun 11; 14(2). PMID: 18543079
Review.
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
Lori J Goldstein, Robert Gray, +12 authors, Joseph A Sparano.
J Clin Oncol, 2008 Aug 06; 26(25). PMID: 18678838    Free PMC article.
Highly Cited.
Trial assessing individualized options for treatment for breast cancer: the TAILORx trial.
Jo Anne Zujewski, Leah Kamin.
Future Oncol, 2008 Oct 17; 4(5). PMID: 18922117
Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model.
Elissa M Ozanne, Dejana Braithwaite, +3 authors, Jeffrey Belkora.
J Clin Oncol, 2008 Dec 03; 27(2). PMID: 19047286
A prognostic index in primary breast cancer.
J L Haybittle, R W Blamey, +5 authors, K Griffiths.
Br J Cancer, 1982 Mar 01; 45(3). PMID: 7073932    Free PMC article.
Highly Cited.
Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study.
Maria B Lyng, Anne-Vibeke Lænkholm, +4 authors, Henrik J Ditzel.
PLoS One, 2013 Jan 24; 8(1). PMID: 23342080    Free PMC article.
Genomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomas.
Anne Vincent-Salomon, Vanessa Benhamo, +13 authors, Olivier Delattre.
PLoS One, 2013 Oct 22; 8(10). PMID: 24143191    Free PMC article.
Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.
P Sinn, S Aulmann, +6 authors, A Schneeweiss.
Geburtshilfe Frauenheilkd, 2014 Apr 29; 73(9). PMID: 24771945    Free PMC article.
Modern Risk Assessment for Individualizing Treatment Concepts in Early-stage Breast Cancer.
Alex Farr, Rachel Wuerstlein, +2 authors, Nadia Harbeck.
Rev Obstet Gynecol, 2013 Jan 01; 6(3-4). PMID: 24920978    Free PMC article.
Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer.
J Stephen, G Murray, +13 authors, J M S Bartlett.
Br J Cancer, 2014 Oct 15; 111(12). PMID: 25314051    Free PMC article.
Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models.
E Laas, P Mallon, +7 authors, F Reyal.
Br J Cancer, 2015 Jan 16; 112(5). PMID: 25590666    Free PMC article.
Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study.
B Yeo, L Zabaglo, +3 authors, M Dowsett.
Br J Cancer, 2015 Jul 17; 113(3). PMID: 26180920    Free PMC article.
Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma.
Arvydas Laurinavicius, Andrew R Green, +4 authors, Ian O Ellis.
Oncotarget, 2015 Oct 30; 6(38). PMID: 26512778    Free PMC article.
Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators?
Sanjoy Chatterjee, Animesh Saha, +5 authors, Rosina Ahmed.
Breast Cancer (Dove Med Press), 2015 Dec 18; 7. PMID: 26677343    Free PMC article.
Patterns in target-directed breast cancer research.
Sofia Torres, Christine Simmons, +3 authors, Maureen Trudeau.
Springerplus, 2016 Feb 16; 5. PMID: 26877907    Free PMC article.
Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application.
Enora Laas, Peter Mallon, +3 authors, Fabien Reyal.
PLoS One, 2016 Feb 20; 11(2). PMID: 26895349    Free PMC article.
Improving the Prognostic Ability through Better Use of Standard Clinical Data - The Nottingham Prognostic Index as an Example.
Klaus-Jürgen Winzer, Anika Buchholz, Martin Schumacher, Willi Sauerbrei.
PLoS One, 2016 Mar 05; 11(3). PMID: 26938061    Free PMC article.
A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2.
Kristian Jensen, Rikke Krusenstjerna-Hafstrøm, +2 authors, Helene Derand.
Mod Pathol, 2016 Oct 22; 30(2). PMID: 27767098
A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer.
Weige Tan, Wei Luo, +6 authors, Chang Gong.
Oncotarget, 2016 Nov 29; 7(52). PMID: 27894097    Free PMC article.
Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).
Bernhard C Pestalozzi, Christoph Tausch, +17 authors, Swiss Group for Clinical Cancer Research (SAKK).
BMC Cancer, 2017 Apr 15; 17(1). PMID: 28407750    Free PMC article.
Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.
A Sheri, I E Smith, +3 authors, M Dowsett.
Breast Cancer Res Treat, 2017 Apr 28; 164(2). PMID: 28447240    Free PMC article.
Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine.
Jane Bayani, Cindy Q Yao, +13 authors, John M S Bartlett.
NPJ Breast Cancer, 2017 Jun 27; 3. PMID: 28649643    Free PMC article.
Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis.
Marina Gándara-Cortes, Ángel Vázquez-Boquete, +10 authors, Tomás García-Caballero.
Virchows Arch, 2017 Aug 22; 472(2). PMID: 28825136
Novel Predictors of Breast Cancer Survival Derived from miRNA Activity Analysis.
Vasily N Aushev, Eunjee Lee, +11 authors, Jia Chen.
Clin Cancer Res, 2017 Nov 16; 24(3). PMID: 29138345    Free PMC article.
Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.
M C U Cheang, J M Bliss, +13 authors, PathIES Sub-Committee.
Breast Cancer Res Treat, 2017 Nov 28; 168(1). PMID: 29177605    Free PMC article.
Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation.
Mustapha Abubakar, Jenny Chang-Claude, +34 authors, Montserrat Garcia-Closas.
Int J Cancer, 2018 Mar 02; 143(4). PMID: 29492969    Free PMC article.
Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.
Mustapha Abubakar, Jonine Figueroa, +8 authors, Paul D Pharoah.
Mod Pathol, 2019 Apr 13; 32(9). PMID: 30976105    Free PMC article.
Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26.
Bradley M Turner, Mary Ann Gimenez-Sanders, +6 authors, David G Hicks.
Cancer Med, 2019 Jun 15; 8(9). PMID: 31199586    Free PMC article.
The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review.
Sophie Gordon-Craig, Ruth M Parks, Kwok-Leung Cheung.
Oncol Ther, 2020 Jul 24; 8(2). PMID: 32700048    Free PMC article.
Review.
Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative.
Paolo Giorgi Rossi, Annette Lebeau, +13 authors, ECIBC Contributor Group.
Br J Cancer, 2021 Feb 19;. PMID: 33597715
Review.